The prognosis in patients with primary brain tumors treated with surgery, radiotherapy and conventional chemotherapy remains poor. To improve outcome, combination high-dose chemotherapy (HDC) has been explored in children, but rarely in adults. This study was performed to determine the tolerability of threedrug combination high-dose thiotepa (T) and etoposide (E)-based regimens in pediatric and adult patients with high-risk or recurrent primary brain tumors. Thirtyone patients (13 children and 18 adults) with brain tumors were treated with high-dose chemotherapy: 19 with BCNU (B) and TE (BTE regimen), and 12 with carboplatin (C) and TE (CTE regimen). Patients received growth factors and hematopoietic support with marrow (n = 15), peripheral blood progenitor cells (PBPC) (n = 11) or both (n = 5). The 100 day toxic mortality rate was 3% (1/31). Grade III/IV toxicities included mucositis (58%), hepatitis (39%) and diarrhea (42%). Five patients had seizures and two had transient encephalopathy (23%). All patients had neutropenic fever and all pediatric patients required hyperalimentation. Median time to engraftment with absolute neutrophil count (ANC) Ͼ0.5 ؋ 10 9 /l was 11 days (range 8-37 days). Time to ANC engraftment was significantly longer (P = 0.0001) in patients receiving marrow (median 14 days, range 10-37) than for PBPC (median 9.5 days, range 8-10). Platelet engraftment Ͼ50 ؋ 10 9 /l was 24 days (range 14-53 days) in children. In adults, platelet engraftment Ͼ20 ؋ 10 9 /l was 12 days (range 9-65 days). In 11 patients supported with PBPC, there was a significant inverse correlation between CD34 + dose and days to ANC (rho = ؊0.87, P = 0.009) and platelet engraftment (rho = ؊0.85, P = 0.005), with CD34 + dose predicting time to engraftment following HDC. Overall, 30% of evaluable patients (7/24) had a complete response (CR) (n = 3) or partial response (PR) (n = 4). Median time to tumor progression (TTP) was 7 months, with an overall median survival of 12 months. These TE-based BCNU or carboplatin three-drug combination HDC regimens are safe and tolerable with promising response rates in both children and older adults.
with an overall median survival of 12 months. These TE-based BCNU or carboplatin three-drug combination HDC regimens are safe and tolerable with promising response rates in both children and older adults. Keywords: combination high-dose chemotherapy; brain tumors; adults; children; CD34 + cells Primary brain tumors are the third leading cause of cancerrelated mortality in young adults 15-34 years old. 1 Conventional-dose chemotherapy for tumors progressing after initial surgery and radiation is ineffective. When all three modalities are combined as initial therapy, the median survival is 12 months and approximately 20% of patients survive 2 years. 2 High-dose chemotherapy (HDC) with agents which can penetrate the CNS is a reasonable strategy to overcome the shortcomings of standard treatment. Combination HDC has been studied in children but minimally in adults with highrisk or recurrent primary brain tumors. Thiotepa (T), etoposide (E), carboplatin (C) and BCNU (B) are non-crossresistant agents with demonstrated activity against gliomas and other brain tumors. 3 They have logarithmic doseresponse curves in vitro, significant CNS penetration, synergistic mechanisms of action, and tolerable, non-overlapping non-hematologic toxicities. These drugs are appropriate for combination in a high-dose regimen with hematopoietic support.
We evaluated combination high-dose regimens of thiotepa and etoposide with BCNU (BTE) or carboplatin (CTE), in children and adults with primary brain tumors.
Patients and methods

Eligibility
Patients were eligible if they had recurrent brain tumors or tumors considered to be at high risk for recurrence despite conventional therapy. Eligible adults were those with newly diagnosed or recurrent glioblastomas (GBM), recurrent anaplastic astrocytomas (AA), recurrent high-grade oligodendrogliomas responsive to conventional chemotherapy, or poor-risk medulloblastomas and primitive neurectodermal tumors (PNET). A Karnofsky score Ͼ70%, no major organ impairment, and no therapy except for corticosteroids or anticonvulsants within 4 weeks of HDC were allowed. Adults were treated on Columbia University institutional protocols.
The pediatric patients were enrolled and treated according to Childrens Cancer Group (CCG 9883) and Memorial Sloan Kettering (MSK 9216, 9064) protocols. The former enrolled children with GBM, AA, medulloblastoma, highgrade ependymoma, pineoblastoma, germ cell tumors and other PNETs that had recurred or progressed on standard chemotherapy. Patients were required to have minimal residual disease, or chemosensitive disease if bulky and unresectable. Pediatric patients eligible for MSK 9216 or 9064 had previously untreated GBM, AA or diffuse intrinsic brain stem tumors. Protocols were approved by the institutional review board and informed consent was obtained according to institutional requirements.
Patients
Thirty-one patients with primary CNS tumors received high-dose thiotepa and etoposide-based regimens and autologous hematopoietic support between April 1990 and February 1997. Patient characteristics are presented in Table 1 . There were 19 males and 12 females. Thirteen were children (Ͻ18 years) and 18 were adults, with a median age of 27 years for the group (range 2-57 years). Thirteen patients were enrolled at initial diagnosis and 18 at recurrence. Four pediatric patients were reported previously. 4, 5 Of 15 patients with gliomas, nine had glioblastomas, three had brain stem gliomas and three had anaplastic astrocytomas. Four patients had anaplastic oligodendrogliomas and one mixed anaplastic oligoastrocytoma. Of nine patients with PNET, six had medulloblastomas, one a pineoblastoma and two had supratentorial PNETs. There was one patient each with ependymoma and nongerminomatous germ cell tumor (NGGCT).
Of the total of 31 patients, 28 (90%) had prior surgery, 
Bone marrow and peripheral blood progenitor cell (PBPC) harvest
PBPC were harvested after mobilization with cyclophosphamide 1.5 g/m 2 and G-CSF. CD34 + enumeration in the leukapheresis product was performed by flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA) as previously described. 6 Both PBPC and harvested marrow were processed, suspended in a 5% DMSO, 4% albumin and 6% hydroxyethyl starch cryopreservation solution, and stored at Ϫ80°C.
High-dose chemotherapy regimens
Thiotepa/etoposide-based regimens and doses used are shown in Table 2 . The BTE regimen included BCNU and a dose escalation of thiotepa in adults. The CTE regimen included carboplatin.
Supportive care
PBPC, marrow or both were reinfused on day 0. Patients received either G-CSF 5-10 g/kg/day or GM-CSF 250 g/m 2 /day from day 0 until white cell count Ͼ5 ϫ 10 9 /l. Hemoglobin was maintained above 8 g/dl. Platelet transfusion was administered to maintain platelets above 50 ϫ 10 9 /l in pediatric patients and 20 ϫ 10 9 /l in adults. Oral antibiotics were commenced at the time of neutropenia. Neutropenic fever was treated with appropriate intravenous antibiotics as necessary. Steroids and anticonvulsants were continued, the latter adjusted to therapeutic levels.
Engraftment was defined as the first of 2 consecutive days on which the patient's absolute neutrophil count (ANC) was Ͼ0.5 ϫ 10 9 /l following the nadir and the first of 5 consecutive days on which the patient's unsupported platelet count was Ͼ20 ϫ 10 9 /l (adult) or Ͼ50 ϫ 10 9 /l (pediatric), the latter level based on the higher incidence of unavoidable minor head trauma in children.
Toxicity and response criteria
Toxicity was graded according to the National Cancer Institute common toxicity criteria and grade 3 and 4 toxicities are reported. Pretransplant and post-transplant gadoliniumenhanced and unenhanced magnetic resonance imaging (MRI) studies performed at least 8 weeks post HDC were compared for assessment of response. Serial scans were performed in most patients every 2-3 months thereafter, or with change in mental status, to monitor progression. Patients with no radiological evidence of disease prior to HDC and without disease post HDC were considered in continuing complete remission (CCR). Complete response was defined as the total disappearance of tumor. Partial response was defined as a greater than 50% reduction of Table 2 High-dose thiotepa and etoposide-based regimens administered to 31 patients with high-risk brain tumors (total dose in mg/m 2 administered in divided dose over 3 or 4 days as indicated) Pediatric  9  900  750  1500  3  4  900  750  600  3   Adult  3  600  1500  1500  3  5  500  1200  450  4  8  600  1200  450  4  2  700  1200  450  4 In children reciving BTE or CTE, B (every 12 h) or C was administered on days Ϫ8 to Ϫ6 and TE on days Ϫ5 to Ϫ3. In adults the CTE regimen was: C over 5 h, T over 5 h and E over 5 h every 12 h, on days Ϫ5 to Ϫ3. For BTE, adult patients received B over 1 h, T as continuous infusion and E over 5 h every 12 h on days Ϫ6 to Ϫ3.
No. of patients Thiotepa (T) Etoposide (E) BCNU (B) Carboplatin (C) Divided over days
the lesion in the product of two diameters at matched anatomic levels on axial or coronal T1-weighted images, a minor response as a 25-50% decrease in this measurement of the tumor. For CR, PR or MR, the corticosteroid dose had to be equal to or lower than at the time of the baseline scan. Stable disease was defined as less than a 25% change in tumor size and progressive disease as a Ͼ25% increase in size. Mixed responses in which tumor decreased in some sites and enlarged in others were designated disease progression. Time to tumor progression (TTP) was defined as the time from HDC to MRI demonstration of disease progression.
Treatment for progression post-HDC treatment
Five patients received radiation therapy and four received chemotherapy at disease progression post high-dose chemotherapy at the discretion of the treating physician.
Statistical analysis
Correlation of total nucleated cells/kg and CD34 + cells/kg to ANC and platelet engraftment was determined by Spearman's correlation. The last date of follow-up was December 1997. Complete follow-up information was available for all patients, except time to progression in one patient with oligodendroglioma. Time to engraftment, progression and overall survival are estimated by the method of KaplanMeier. Differences in days to engraftment for patients receiving marrow or blood-derived stem cells, and outcome between patients with regard to age, regimen, tumor type and with residual tumor Ͻ or Ͼ2 cm were analyzed by the log rank test of Mantel. Clinical and laboratory data were analyzed in Statview v 4.5 (Abacus Concepts, Berkeley, CA, USA).
Results
Hematological toxicity and recovery
PBPC (11 patients), marrow (15 patients) or both (five patients) were reinfused on day 0. Patients received a median of 5.3 ϫ 10 8 (range 1.68-29.68) total nucleated cells (TNC)/kg.
One patient died with culture negative sepsis at day 7 without engrafting. For the surviving patients, the median time to ANC engraftment Ͼ0.5 ϫ 10 9 /l was 11 days (range 8-37 days). There was a poor inverse correlation between TNC/kg infused and time to ANC engraftment (rho = Ϫ0.34, P = 0.07). Time to ANC engraftment was significantly longer (P = 0.0001) in patients receiving marrow alone (median 14 days, range 10-37) than for PBPC (median 9.5 days, range 8-10). In pediatric patients all but one of whom received marrow alone, the median time to platelet engraftment Ͼ50 ϫ 10 9 /l was 25 days (range 14-53 days). In adults, the median time to platelet engraftment Ͼ20 ϫ 10 9 /l was 12 days (range 9-65 days). The 11 patients supported with PBPC received a median of 3.17 ϫ 10 6 CD34 + cells/kg (range 1.0-7.79). Eight patients had received prior standard-dose BCNU (median of 1 cycle, range 1-2) and 10 patients received cranial irradiation, prior to HDC. The dose of CD34
+ cell reinfused in these patients correlated inversely with days to ANC (rho = Ϫ0.87, P = 0.009) and platelet engraftment (rho = Ϫ0.85, P = 0.005).
All patients required blood and platelet support. Hospital stay was a median of 23 days (range 14-113).
Febrile episodes and infections
All patients experienced febrile neutropenic episodes requiring broad-spectrum antibiotics. Bacteremia was documented in six patients. Two patients had fungal infections: one patient had multiple bacterial infections, MAI and pulmonary aspergellosis and the second patient had candidia infection treated with Amphotericin B (Gensia Laboratories, Irvine, CA, USA). One patient was diagnosed with CMV enteritis.
Non-hematopoietic toxicities
The overall toxic mortality rate was 3% (1/31): a 39-yearold man with GBM treated with BTE, died from culture negative sepsis on day 7 post PBPC re-infusion. No toxic deaths occurred in patients receiving CTE.
Grade 3/4 toxicities are shown in Table 3 . All patients experienced some nausea, vomiting and mucositis, and all pediatric patients required hyperalimentation. One child 
Response to therapy and survival
Seven patients had no evidence of disease at the time of HDC. Three of these patients with PNET progressed at 2, 6 and 9 months and died at 4, 6 and 36 months, respectively. One patient with glioblastoma is alive with progression at 10+ months. One patient with oligodendroglioma and two with PNET have not progressed at 42+, 35+ and 52+ months respectively. Of patients with evaluable disease, 7/23 (30%) had a CR (n = 3) or PR (n = 4) following HDC (Table 4 ). Among these were four patients with recurrent disease who had CR (n = 2) and PR (n = 2). One patient had a MR, 11 patients had SD and four patients had PD. Overall median time to tumor progression (TTP) was 7 months (Figure 1) .
The overall median survival was 12 months (Figure 1 ). Survival in patients having a complete response to chemotherapy is 13+ months for glioblastoma, 15 months for anaplastic oligodendroglioma, and 12 months for PNET. Patients with PNET had longer median survival (18 months) than those with anaplastic astrocytomas (15 months) or glioblastomas (9 months) but this was not statistically significant. Tumor burden was assessed radiologically at the time of high-dose chemotherapy. Twelve patients had tumors of Ͼ2 cm in diameter, and 19 had disease of Ͻ2 cm in diameter, including seven patients with no evidence of disease at the time of HDC. Patients with tumors Ͼ2 cm in diameter prior to high-dose chemotherapy had a statistically significant shorter median survival of 9 months as compared to 17 months in patients with tumors Ͻ2 cm in diameter (log rank P = 0.05). Time to tumor progression was not statistically different (6 vs 7 months, P = 0.3). Age and regimen did not significantly influence overall survival. One fully engrafted adult GBM patient with recurrent deep venous thromboses, decreasing mental status and multiple medical problems, died of untreated pneumonia at a hospice at 4 months, without evidence of disease progression by MRI. All other non-toxic deaths were due to disease progression. Seven patients remain alive, three of 13 treated with high-dose chemotherapy at initial presentation (GBM 10+, 13+; PNET 52+ months without disease); and four of 18 treated for recurrent disease (AA 23+; oligo 21+, 42+; PNET 35+ months), two of whom (oligo 42+ and PNET 35+ months) are without disease.
Discussion
Bone marrow was initially used for hematopoietic support in our patients. Recent results have shown mobilized PBPCs provide successful engraftment with less morbidity and PBPCs are now our preferred method of hematopoietic support. 7 Mobilization of PBPCs with 1.5 g/m 2 cyclophosphamide and G-CSF was successful in all cases. Our results confirm that hematologic recovery is significantly more rapid in patients receiving PBPC support than marrow.
There was a good inverse correlation between PBPC CD34 + dose and time to ANC and platelet engraftment in patients, with у1 ϫ 10 6 CD34 + cells/kg ensuring rapid and sustained engraftment in this relatively small sample. We were initially concerned that prior radiation and chemotherapy, particularly BCNU, might compromise both the collection of adequate cells for hematopoietic support and their engraftment. 8 Factors such as prior radiation and chemotherapy may also influence platelet engraftment to a greater degree than granulocytes. 6 None the less, for our patients with brain tumors undergoing high-dose chemotherapy, CD34
+ cell number was a useful predictor of time to ANC and platelet engraftment. Furthermore, adequate numbers of PBPC could be harvested and prompt engraftment after high-dose chemotherapy was observed.
To date, most studies of high-dose chemotherapy for brain tumors have explored two-drug combination HDC in the pediatric population.
9-13 A goal of our study was to demonstrate that combination HDC could be performed with acceptable morbidity in both children and older adults with high-risk and recurrent brain tumors. The majority of our pediatric patients were entered on a protocol utilizing a CTE-based HDC regimen, while most adult patients received BTE. One of 15 adult patients treated with BTE died, resulting in a 5% mortality rate for adults with this regimen. There were no toxic deaths in patients receiving CTE. Although the number of adults treated with BTE in our study is small, these patients tolerated this combination well. Dunkel and Finlay 14 reported a toxic mortality rate of 22% in 37 patients with newly diagnosed or recurrent highgrade astrocytoma treated with BTE and autologous bone marrow rescue. As three deaths occurred in the five patients Ͼ30 years who received BTE and involved field radiation, this trial was discontinued in patients Ͼ25 years of age. The lower doses of BTE in our study, as well as more rapid hematopoietic engraftment with PBPCs, may account for our lower mortality rate.
By comparison, mortality rates for other combination drug regimens have ranged from 3 to 22% respectively. [9] [10] [11] [12] [13] 15, 16 ( Table 5) . We have thus shown that a BCNU containing three-drug regimen supported with PBPCs is relatively safe even for patients over the age of 25. Given the caveat that the numbers of patients treated with each regimen in this study is relatively small, we could not demonstrate any benefit of the BCNU regimen over the non-BCNU containing regimen. Single agent high-dose BCNU has been adequately evaluated both in the context of recurrent brain tumors and adjuvant therapy. 3 While resulting in higher response rates than conventional therapy, overall survival was not substantially influenced in patients with recurrent tumors. 17, 18 Adjuvant high-dose BCNU appears more encouraging, particularly in patients with complete macroscopic tumor resection. 19 Hence, further study using highdose BCNU in combination HDC regimens is warranted given the historical data supporting the value of BCNU at both standard and high doses in adults with brain tumors. 2, 3 The primary purpose of our study was to demonstrate the tolerability of the three-drug combination HDC regimens. Twenty-three patients were also evaluable for response, and the overall response rate was 30%. Response rates for gliomas or PNET were 22 and 50%, respectively. The one CR and two PRs achieved with BTE in patients with highgrade gliomas is encouraging, as is the CR and PR achieved in two of four evaluable patients with recurrent PNET given CTE. In patients with recurrent CNS tumors treated with high-dose thiotepa and etoposide alone, Finlay et al 9 reported response rates of 29% for gliomas and 33% for PNET or medulloblastoma. Using a thiotepa and busulfan HDC regimen, Kalifa et al 11 showed a response rate of 38% in PNET or medulloblastomas and no response in glioblastomas. In a subsequent study, of 16 evaluable pediatric patients with relapsed medulloblastomas, the response rate with this regimen was 75%. 20 With a cyclophosphamide and melphalan regimen in 19 patients, a 39% response rate was reported by Mahoney et al. 13 Again, in this study responses occurred in medulloblastoma and germinoma patients but not in patients with malignant gliomas.
In our study, time to progression and overall survival were longer for patients with PNET than other tumor types, but this difference was not statistically significant. While the median survival was similar to that for conventional therapy, a fraction of patients has not yet relapsed, some with relatively long follow-up. Cumulative data from most HDC trials in recurrent gliomas suggest that although the median survival does not differ significantly when compared with patients treated with standard therapy, there are a few long-term survivors, even in heavily pretreated patients. 10, 12 The reports of even a few long-term survivors are significant in a tumor that is virtually uniformly fatal with conventional treatment. In pediatric patients with relapsed medulloblastomas, those with local recurrence appeared to derive most benefit from HDC. 20 Using a cyclophosphamide and melphalan HDC regimen, Graham et al 15 reported that patients with local recurrence of medulloblastoma and PNET benefited most from this high-dose regimen.
Patients with residual tumors smaller than 2 cm in diameter survived longer in our study, presumably because patients with smaller amounts of disease or lower stage generally survive longer. In view of the small sample size, these findings need to be interpreted with caution. Finlay et al 9 have reported similar observations. We found no significant difference in progression-free survival, in contrast to Mahoney et al, 13 who reported a longer progression-free survival in patients with minimal disease.
The mortality after HDC and autologous stem cell transplant was low (3%) in our study, and does not differ significantly from the 1-4% mortality associated with conventional-dose chemotherapy. HDC is as yet of unproven benefit. In the light of our promising response rates, further studies of patients with optimally debulked tumor treated with radiotherapy and timely initiation of adjuvant HDC may more clearly identify a subset of patients with specific tumor subtypes who might derive long-term benefit from this aggressive therapeutic approach. The strategy of doseintensification using combination chemotherapy should be more effective in a patient population already in CR and in those with less prior treatment. The results of the few published trials, including the present study, in which highdose chemotherapy was evaluated in some patients as part of their initial treatment are encouraging. Dose-intensive therapy in the post-operative setting is clearly feasible. Treatment-related mortality in five single agent adjuvant trials ranged between 0 and 27%, with 16 of 190 patient (9.4%) dying of treatment-related complications. 3 To avoid the toxicity of chemotherapy in those patients who are unlikely to benefit, the identification of reliable biomarkers that predict response to chemotherapy is needed. 21 In appropriately selected patients, the combination of three active and non-cross-resistant agents in a high-dose regimen as part of an aggressive multimodality approach in the adjuvant setting is a tolerable strategy that deserves further evaluation.
